m6A RNA methylation modulates antiviral response in celiac disease

Area of Science:

• Immunology
• Molecular Biology
• Gastroenterology

Background:

• Celiac disease involves autoimmune tissue damage, with N6-methyladenosine (m6A) RNA modifications and reovirus infections emerging as potential contributors.
• The interplay between viral infections, RNA modification machinery, and autoimmune pathogenesis is not well understood.

Purpose of the Study:

• To investigate the link between m6A methylation, viral infections, and autoimmune inflammation in celiac disease.
• To explore the role of m6A in regulating antiviral gene expression and its potential as a therapeutic target.

Main Methods:

• Utilized an in vitro model with a viral mimic and gliadin peptides to simulate celiac disease conditions.
• Analyzed serum and intestinal biopsies from celiac disease patients and controls.
• Investigated the expression of IRF7 and its regulation by m6A methylation and YTHDC2.

Main Results:

• Patients showed elevated anti-reovirus reactivity, increased antiviral gene expression, and enhanced m6A levels.
• Combined exposure to viral mimic and gliadin synergistically induced IRF7 expression via m6A methylation and YTHDC2 interaction.
• METTL3 silencing or simvastatin treatment reduced m6A, IRF7 methylation, and pro-inflammatory gene expression.

Conclusions:

• m6A RNA methylation acts as a key modulator of antiviral responses in the context of celiac disease.
• Targeting m6A methylation pathways presents a potential therapeutic strategy for autoimmune disorders like celiac disease.